|Bid||0.3710 x 1000|
|Ask||0.3800 x 800|
|Day's Range||0.3620 - 0.4044|
|52 Week Range||0.2500 - 5.8900|
|Beta (3Y Monthly)||2.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.60|
Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) continues its loss-making streak, announcing negative earnings for its...
Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Aug. 06, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and six months ended June 30, 2019, and provided.
Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shareholders should be happy to see the share price up 21% in the last...
Did an iceberg just wallop into Conatus (CNAT) stock? This biotech company's shares plunged yesterday at breakneck speed of almost 70%. The reason? Conatus’ lead drug Emricasan failed a mid-stage trial in patients with nonalcoholic steatohepatitis-related decompensated cirrhosis.Emricasan – an oral pan-caspase inhibitor that targets nonalcoholic steatohepatitis – has gone through several trials over the last three years. This recent phase 2b trial was conclusive enough for Conatus to forgo any further testing, after the trial clearly proved the drug is not an effective treatment.Amidst uncertainty about Conatus’ strategic options, H.C. Wainwright analyst Ed Arce has removed his price target on CNAT stock, while maintaining a Neutral rating. (To watch Arce's track record, click here)Conatus projects its cash and equivalents at the end of 2019 to be in the range of $10M to $15M. The company also announced that 40% of their staff were laid off after the failure and suspension of the 2b trial.Arce believes that it is incredibly challenging to value the company during this period of cash preservation and strategic re-evaluation. With the termination of the development program for Emricasan, Conatus is currently focused on finding a strategic purchaser who sees value in the CTS-2090 compound used in Emricasan and the expertise of the remaining employees. With a market cap of $9.64M, it appears that the market is pricing in the possibility of bankruptcy, as the company is being valued below Conatus’ projections of end-of-year 2019 cash and equivalents.Arce believes the main concern is that if the company cannot find a strategic acquirer before their cash runs dry, they are at seriously risk of going into bankruptcy.TipRanks suggests caution roars loud on Wall Street for sell-side analysts sizing up the challenged drug maker's prospects. Out of 4 analysts polled in the last 12 months, all 4 are sidelined on CNAT stock. (See CNAT's price targets and analyst ratings on TipRanks) More recent articles from Smarter Analyst: * 3 Monster Growth Stocks That Will Keep Soaring in 2020 * New Age Beverages (NBEV): Don’t Chase Headlines * 3 'Strong Buy' Energy Stocks to Consider Ahead of Earnings * Goldman Sachs: 3 Buy-Rated Stocks That Could Soar
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.
Shares of micro-cap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) were sinking further into penny stock territory Tuesday after two announcements made Monday after the market close. Conatus said it has engaged Oppenheimer to explore strategic alternatives in a bid to enhance shareholder value.
Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial. The drug was being developed to treat patients with nonalcoholic steatohepatitis (NASH), a fatty liver disease where fat accumulation and inflammation can lead to scarring, or fibrosis, that impairs liver function. Novartis AG in 2017 had exercised its option with Conatus to develop emricasan.
Conatus Pharmaceuticals Inc. (CNAT) today announced that the company has engaged Oppenheimer & Co., Inc., as its financial advisor to assist in the exploration and evaluation of strategic alternatives to enhance shareholder value. In order to extend its resources, Conatus is implementing a restructuring plan that includes reducing staff by approximately 40% and suspending development of its inflammasome disease candidate, CTS-2090. The company has updated its financial guidance and is projecting a year-end 2019 net balance of cash, cash equivalents and marketable securities of between $10 million and $15 million.
Conatus Pharmaceuticals Inc. (CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the company is discontinuing further treatment of patients enrolled in the ENCORE-LF clinical trial. Also, results from the 24-week extension in the company’s ENCORE-PH clinical trial of emricasan were consistent with results from the initial 24-week treatment period and did not meet predefined objectives. Conatus will continue to work with its partner Novartis on ensuring that all remaining obligations related to the emricasan program are fulfilled. The randomized, double-blind ENCORE-LF Phase 2b clinical trial, initiated in the second quarter of 2017, enrolled 217 patients with decompensated NASH cirrhosis.
Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.
Every investor in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) should be aware of the most powerful shareholder groups...
Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 14 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...